Drugs / MOZAFANCOGENE AUTOTEMCEL
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03814408 | Jan 2019 → Dec 2020 | Fanconi anemia complementation group A | Rocket Pharmaceuticals Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04248439 | Jul 2020 → May 2026 overdue | Fanconi anemia complementation group A | Rocket Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04069533 | Nov 2019 → Feb 2025 | Fanconi anemia complementation group A | Rocket Pharmaceuticals Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MOZAFANCOGENE AUTOTEMCEL | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802257 ↗ |
| Known as | RP-L102 | “RP-L102 is CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with lentiviral vector carrying the FANCA gene” NCT04069533 ↗ |
| Modality | Cell therapy | “hematopoietic gene therapy consisting of autologous CD34+ enriched cells transduced with a lentiviral vector carrying the FANCA gene” NCT04248439 ↗ |
| Route | Intravenous | “Investigational product will be infused via intravenous infusion” NCT03814408 ↗ |